If you have been reading about AOD9604 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-07-08. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
== The cladistic turn (1970s–1990s) == By the late 20th century lichen systematics adopted the quantitative, computer-aided methods gaining ground across biology. Numerical taxonomy (phenetics) and cladistics entered lichenology, paralleling their uptake in plant and animal studies. Researchers replaced qualitative judgement with data matrices that coded morphological, chemical, and anatomical characters, then applied algorithms to infer relationships. Phenetic studies of the 1970s grouped lichens with clustering routines; in the 1980s Willi Hennig's cladistics shifted focus to shared-derived characters (synapomorphies) for reconstructing evolutionary trees. The shift required clear definitions of characters and explicit decisions about which traits were primitive or derived. Analyses became repeatable and easy to update as new characters or taxa were added. Robert Lücking (2020) called this methodological turn a milestone on par with the invention of the microscope for taxonomy. The new methods added rigour and standardization, aligning lichen systematics with broader evolutionary biology. Manuals on numerical and cladistic techniques were widely adopted, and phylogenetic workshops became regular features of lichen conferences. Cladistic rigour prompted a reassessment of single-trait classifications. Earlier systems frequently anchored families or genera on a single trait—spore septation, a particular metabolite, and so on. Cladistic analyses showed that such one-character groupings often masked true relationships.
A radionuclide (radioactive nuclide, radioisotope, radioactive isotope, or unstable isotope) is a nuclide that is unstable and known to undergo radioactive decay into a different nuclide, which may be another radionuclide (see decay chain) or be stable. Radioactive decay is a random process at the level of single atoms: it is impossible to predict when one particular atom will decay. For a collection of atoms of a single nuclide, their average decay rate can be measured, and its half-life (t1/2) calculated. Half-lives vary by 55 orders of magnitude and have no known limits. All chemical elements have radionuclides - even the lightest, hydrogen, has a well-known radionuclide, tritium (though helium, lithium, and boron have none with half-life over a second). Elements heavier than lead (Z > 82), and the elements technetium and promethium, have only radionuclides and do not exist in stable forms, though bismuth can be treated as stable with the half-life of its natural isotope being over a trillion times longer than the current age of the universe. Radiation emitted by radionuclides is almost always ionizing radiation and exposure above a certain level can cause damage to living organisms.
=== Sexual assault charge === In April 2026, Aleksandra Vasilevna Mendoza filed a lawsuit against Peters alleging fraud, infliction of emotional distress, and battery, relating to an incident in 2025. At the time in question, Mendoza had begun working with Peters. Mendoza alleged that he sexually assaulted her, and also injected her with a drug in her face, called Aqualyx, during the encounter. Her complaint alleged that his actions had led to "severe emotional distress, trauma, humiliation, nightmares, fear, panic, and mental anguish." Peters' lawyer responded to the accusations saying, "These are allegations only and remain unproven. Mr. Peters denies the claims and disputes the characterization of events." On September 8, 2026, charges were filed against Peters in Massachusetts for criminal rape, drugging, and providing alcohol to a minor. The charges related to an incident that is alleged to have occurred on May 23, 2025 in which Peters is accused of giving vodka to a 17-year-old girl on a livestream and having sex with her several times afterward, when she was unable to consent. Peters' arraignment is scheduled for October 14, 2026.
=== Electric fishes === The Gymnotiformes of South America and the Mormyridae of Africa independently evolved passive electroreception (around 119 and 110 million years ago, respectively). Around 20 million years after acquiring that ability, both groups evolved active electrogenesis, producing weak electric fields to help them detect prey.
Sources: en.wikipedia.org
This relates to having an increased risk of a woman bearing fraternal twins because higher levels of FSH will produce more eggs. The more eggs a woman produces increases the chance of multiple eggs ovulating and becoming fertilized by sperm. In retrospect, depending on the type of variation, the FSHB gene could potentially cause infertility by the inability to produce enough FSH, in both males and females. Additionally, low or no FSH can result in delayed puberty and risk of disease. Diseases associated with FSHB variants are hypogonadism, hypogonadotropic hypogonadism type 24 (HH24), and type 7 (HH7), and are possibly linked to polycystic ovary syndrome.
By 1986, the task force had made over 15,000 arrests and seized over six million pounds of cannabis and 100,000 pounds of cocaine, doubling cocaine seizures annually – administration officials called it Reagan's biggest drug enforcement success. However, law enforcement agents at the time said their impact was minimal; cocaine imports had increased by 10%, to an estimated 75–80% of America's supply. According to the head of the task force's investigative unit, "Law enforcement just can't stop the drugs from coming in." A Bush spokesperson emphasized disrupting smuggling routes rather than seizure quantities as the measure of success." In 1984, Reagan signed the Comprehensive Crime Control Act, which included harsher penalties for cannabis cultivation, possession, and distribution. It also established equitable sharing, a new civil asset forfeiture program that allowed state and local law enforcement to share the proceeds from asset seizures made in collaboration with federal agencies. Under the controversial program, up to 80% of seizure proceeds can go to local law enforcement, expanding their budgets. By 2019, $36.5 billion worth of assets had been seized, much of it drug-related, much of it distributed to state and local agencies.
==== Pancreatic and glycemic control ==== GLP-1 receptor activation slows gastric emptying, inhibits the release of glucagon, and stimulates insulin production, thereby improving glucose homeostasis in people with type 2 diabetes. At the cellular level, binding to the GLP-1 receptor on pancreatic beta cells elevates intracellular cyclic AMP (cAMP) and activates protein kinase A (PKA). This cascade triggers the influx of calcium, which directly prompts the exocytosis of insulin-containing vesicles. Furthermore, GLP-1 agonists actively ameliorate peripheral insulin resistance by upregulating phosphorylated IRS-1 and promoting the transport of the GLUT4 transporter to cell membranes in muscle and adipose tissue.
Sources: en.wikipedia.org
=== Additional views === Decubitus – taken while the patient is lying down, typically on their side. Useful for differentiating pleural effusions from consolidation (e.g. pneumonia) and loculated effusions from free fluid in the pleural space. In effusions, the fluid layers out (by comparison to an up-right view, when it often accumulates in the costophrenic angles). Lordotic view – used to visualize the apex of the lung, to pick up abnormalities such as a Pancoast tumor. Expiratory view – helpful for the diagnosis of pneumothorax. Oblique view – useful for the visualization of the ribs and sternum. Although it is necessary to do the appropriate adaptations to the x-ray dosage to be used.
== Presentation == MFS usually afflicts individuals in their fifth to seventh decades of life although uncommon cases occur in adults outside of this age range In one large study, MFS was diagnosed in individuals 21 to 96 years old (median age 66 years). Most studies have diagnosed MFS slightly more often in men than women but one large study conducted in France found it to be 50% more common in men. Individuals with MFS present with a tumor located in an extremity (77% of cases, usually in the lower extremity), trunk (12% of cases), and head and neck areas (3% of cases). Rarely, these tumors have presented in the breast, heart, paratesticular region (i.e. area inside the scrotum including the epididymis the spermatic cord along with its coverings), eye, bone, liver, or multiple sites concurrently. Primary tumors presenting in the abdominal cavity, retroperitoneum, or pelvis have been diagnosed as MFS but larger studies indicate that these tumors are far more likely to be dedifferentiated liposarcomas. MFS tumors usually develop as painless, slowly enlarging masses in a muscle, skin (usually below the fascia i.e. a sheet of connective tissue, primarily collagen, running beneath the skin), or one of the non-cutaneous areas described above. In one study of 69 FBS cases 36 were <5 cm, 23 were between 5 and 10 cm, and 19 were > 10 cm in diameter with the largest tumor being 27 cm. MFS tumors often infiltrate along vascular and fascial planes, are incompletely removed at surgery, and consequently recur at the surgical site.
Of these, high-pressure gas cylinders and liquid hydrogen in cryogenic tanks are the least practical ways to store hydrogen for the purpose of fuel due to the high pressure required for storing hydrogen gas or the low temperature required for storing hydrogen liquid. The other methods are all being studied and developed extensively.
In this area of research, the 20 encoded proteinogenic amino acids are referred to as standard amino acids, or alternatively as natural or canonical amino acids, while the added amino acids are called non-standard amino acids (NSAAs), or unnatural amino acids (UAAs; term not used in papers dealing with natural non-proteinogenic amino acids, such as phosphoserine), or non-canonical amino acids.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.